Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis ; volume:38 ; number:12 ; day:8 ; month:8 ; year:2019 ; pages:3381-3390 ; date:12.2019
Clinical rheumatology ; 38, Heft 12 (8.8.2019), 3381-3390, 12.2019
- Urheber
-
Edwards, Christopher J.
Monnet, Joëlle
Ullmann, Martin
Vlachos, Pantelis
Chyrok, Veranika
Ghori, Vishal
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-019-04679-y
- URN
-
urn:nbn:de:101:1-2020051022202678777882
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Edwards, Christopher J.
- Monnet, Joëlle
- Ullmann, Martin
- Vlachos, Pantelis
- Chyrok, Veranika
- Ghori, Vishal
- SpringerLink (Online service)
Ähnliche Objekte (12)
AVT02: An Adalimumab Biosimilar
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Correction to: AVT02: An Adalimumab Biosimilar
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Correction to: AVT02: An Adalimumab Biosimilar
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Correction to: AVT02: An Adalimumab Biosimilar
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab